Livongo, which sells connected devices to monitor diabetes, files for an IPO, says it had $32.06M in revenue in Q1 2019 with a net loss of $14.96M
KEY POINTS — The company provide tools for people with chronic disease, and works with some 600 employers and health plans.
Context & Ripple Effects
Livongo's filing caps a fast private run: just over a year after its $105M Series E at an $800M+ valuation, the diabetes-device maker is going public on a model of selling connected monitors plus a cloud platform to some 600 employers and health plans. The S-1 discloses the trade-off behind that distribution-first strategy — $32.06M in Q1 2019 revenue against a $14.96M net loss.
The filing also lands mid a liquidity wave: sources say Livongo, One Medical, and Teladoc together raised about $1.6B in convertible notes in the prior month, so public investors are being asked to price several digital-health balance sheets at once.
First-order effects
- Public-market scrutiny now falls directly on Livongo's unit economics: the loss-making quarter means the roadshow has to sell employer and health-plan distribution as the asset, not current profitability.
- The company converts its recent convertible-note raise into an equity story, giving note holders a marked-up exit path through the offering.
Second-order effects
- A strong debut would reopen the digital-health IPO window for peers — Amwell's later confidential filing shows telemedicine companies queuing behind the same thesis.
- Teladoc, already a fellow fundraiser in that convertible-note cohort, ends up watching Livongo's chronic-care platform mature as both a competitor and an acquisition target — which is exactly what happens in the $18.5B Teladoc buyout a year later.
Third-order effects
- If the pattern holds, virtual chronic care consolidates around scaled telehealth platforms rather than staying a field of independent device-plus-software vendors, with Livongo's IPO that raised $350M+ and closed up 36% serving as the template Omada Health followed in its own 2025 debut.
- Employers and health plans gain leverage as buyers: once chronic-care vendors are public and comparable, contracting shifts toward whoever can prove outcomes across the largest member base.
The trend: Virtual chronic care is maturing from venture-backed device sellers into publicly traded platforms that telehealth incumbents ultimately absorb, with each IPO repricing the next.